Volume 19, Issue 6 (Iranian South Medical Journal 2017)
Iran South Med J 2017, 19(6): 940-950 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Motevalizadeh Ardekani A, Shirani M, Hashemi A, Basiri Z, Rahmati Y, Nikbakhsh N, et al . Methylation Status of NANOG1, RASSF1A, SFN, CASP8, WIF1,CTSL2 Genes in Iranian Breast Cancer Patients. Iran South Med J 2017; 19 (6) :940-950
URL: http://ismj.bpums.ac.ir/article-1-842-en.html
URL: http://ismj.bpums.ac.ir/article-1-842-en.html
Ali Motevalizadeh Ardekani * 
1, Mahsa Shirani2 , Ahmad Hashemi2 , Zohre Basiri2 , Yazdan Rahmati2 , Novin Nikbakhsh3 , Sahar Edrisi3 , Shahla Mohammadganji2
1, Mahsa Shirani2 , Ahmad Hashemi2 , Zohre Basiri2 , Yazdan Rahmati2 , Novin Nikbakhsh3 , Sahar Edrisi3 , Shahla Mohammadganji2
1- Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran , Ardekani@nigeb.ac.ir
2- Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
3- Cancer Research Center, Babol University of Medical Sciences, Babol, Iran
2- Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
3- Cancer Research Center, Babol University of Medical Sciences, Babol, Iran
Abstract: (8915 Views)
Background: Mammographic screening to diagnose the breast cancer showe false-negative and false-positive results in young women and therefore a non-invasive and low cost method is needed, to diagnose the breast cancer in the early stages. DNA methylation changes are the most common molecular changes in human cancers and including breast cancer. Therefore, The pattern of tissues methylation can be used in the early diagnosis of cancer. Also similar methylation patterns found in tumors and in plasma shows potential application of molecular detection of breast cancer, based on blood. The aim of this study was to assess the promoter methylation for the clinical diagnosis of breast cancer.
Material and Methods: To examine the promoter methylation 21 tumor tissues and 21 normal tissues have been studied for clinical diagnosis of breast cancer. 6 gene methylation status (NANOG1, RASSF1A, SFN, CASP8, WIF1 and CTSL2) was analyzed by methylation specific PCR (MS-PCR).
Results: The results show that NANOG gene was methylated in 94.7% of tumor specimen and 100% of normal specimen, RASSF1A gene was methylated in 9.5% of tumor specimen and 0% of normal specimen, SFN gene was methylated in 14.3% of tumor specimen and 27.8% of normal specimen, CASP8 gene was methylated in 30% of tumor specimen and 23.5% of normal specimen, WIF1 gene was methylated in 80% of tumor specimen and 27.8% of normal specimen, CTSL2 gene was methylated in 28.6% of tumor specimen and 23.5 % of normal specimen were methylated. Data analysis did not show a significant relationship between these results. (P >0.05).
Conclusion: The results of this study demonstrate that 6 gene methylation status was not enough to differentiate between the cancer and normal groups. This study demonstrates the methodological problems (MS PCR) which was used to assess the methylation markers to evaluate the methylation status as diagnostic biomarkers.
Subject:
Biochemistry. Cell Biology and Genetics
Received: 2015/10/20 | Accepted: 2016/01/23 | Published: 2016/12/27
Received: 2015/10/20 | Accepted: 2016/01/23 | Published: 2016/12/27
References
1. Pal R, Srivastava N, Chopra R, et al. Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology. Mol Cancer 2010; 9: 303-9. [PubMed] [Google Scholar]
2. Mousavi SM, Montazeri A, Mohagheghi MA, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4): 383-91. [PubMed] [Google Scholar]
3. Taghavi A, Fazeli Z, Vahedi M, et al. Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev 2012; 13(1): 367-70. [PubMed] [Google Scholar]
4. Debald M, Franken S, Heukamp LC, et al. Identification of specific nuclear structural protein alterations in human breast cancer. J Cell Biochem 2011; 112(11): 3176-84. [PubMed] [Google Scholar]
5. Daniel FI, Cherubini K, Yurgel LS, et al. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011; 117(4): 677-87. [PubMed] [Google Scholar]
6. Pogribny IP. Epigenetic events in tumorigenesis: putting the pieces together. Exp Oncol 2010; 32(3): 132-6. [PubMed] [Google Scholar]
7. Van De Voorde L, Speeckaert R, Van Gestel D, et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 2012; 751(2): 304-25.
8. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004; 68(6): 1187-97. [PubMed] [Google Scholar]
9. Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64(13): 4442-52. [PubMed] [Google Scholar]
10. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN1, RAR-beta, Cyclin D2 and Twist in situ and invasive lobular breast carcinoma. Ine J Cancer 2003; 107(6): 970-5. [PubMed] [Google Scholar]
11. Parrella P, Poeta ML, Gallo AP, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004; 10(16): 5349-54. [PubMed] [Google Scholar]
12. Ahmed IA, Pusch CM, Hamed T, et al. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet Cytogenet 2010; 199(2): 96-100. [PubMed] [Google Scholar]
13. Bai L, Deng X, Li Q, et al. Down-regulation of the cavin family proteins in breast cancer. J Cell Biochem 2012; 113(1): 322-8. [PubMed] [Google Scholar]
14. Jeter CR, Badeaux M, Choy G, et al. Functional evidence that the selfrenewal gene NANOG regulates human tumor development. Stem Cells 2009; 27(5): 993-1005. [PubMed] [Google Scholar]
15. Brooks JD, Cairns P, Shore RE, et al. DNA methylation in pre-diagnostic serum samples of breast cancer cases: Results of a nested case-control study. Cancer Epidemiol 2010; 34(6): 717-23. [PubMed] [Google Scholar]
16. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control 2009; 20(9): 1539-50. [PubMed] [Google Scholar]
17. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003; 3(12): 931-43. [PubMed] [Google Scholar]
18. Kruidering M, Evan GI. Caspase-8 in Apoptosis: The Beginning of “The End”. IUBMB Life 2000; 50(2): 85-90. [PubMed] [Google Scholar]
19. Santamaría I, Velasco G, Cazorla M, et al. Cathepsin L2, A novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res 1998; 58(8): 1624-30. [PubMed] [Google Scholar]
20. Shepelev MV, Korobko EV, Korobko IV. WIF1: perspectives of application in oncology. Mol Gen Mikrobiol Virusol 2005; (4): 3-7. [PubMed] [Google Scholar]
21. Bae YK, Shim YR, Choi JH, et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat 2005; 37(4): 233-40. [PubMed] [Google Scholar]
22. Bardowell SA, Parker J, Fan C, et al. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treatment 2013; 142(2): 365-80. [PubMed] [Google Scholar]
23. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21. 3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61(7): 3105-9. [PubMed] [Google Scholar]
24. Martínez-Galán J, Torres B, Del Moral R, et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Therapy 2008; 7(6): 958-65. [PubMed] [Google Scholar]
25. Yamamoto N, Nakayama T, Kajita M, et al. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 2012; 132(1): 165-73. [PubMed] [Google Scholar]
26. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97(11): 6049-54. [PubMed] [Google Scholar]
27. Zurita M, Lara PC, del Moral R, et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 2010; 10: 217. [PubMed] [Google Scholar]
28. Mhawech P, Benz A, Cerato C, et al. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 2005; 18(3): 340-8. [PubMed] [Google Scholar]
29. Wu Y, Alvarez M, Slamon DJ, et al. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer 2010; 10: 32. [PubMed] [Google Scholar]
30. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Diff 2003;10(3): 356-64. [PubMed] [Google Scholar]
31. Wang XQ, Ng RK, Ming X, et al. Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines. PLoS One 2013; 8(9): e72435. [PubMed] [Google Scholar]
32. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61(7): 3105-9. [PubMed] [Google Scholar]
33. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93(9): 691-9. [PubMed] [Google Scholar]
34. Veek J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15(1): 5-17. [PubMed] [Google Scholar]
35. Zare M, Rastgar Jazii F, Alivand MR, et al. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cance 2009; 9: 24. [PubMed] [Google Scholar]
36. Rasti M, Arabsolghar R, Azmand S. Methylation Status of Tumor-Related Genes in Mcf7, Mda-Mb-468 and Bt-474 Breast Cancer Cell Lines with Different Estrogen Receptor Status. Middle East J Cancer 2014; 5(4): 207-13. [Google Scholar]
37. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55(20): 4525-30. [PubMed] [Google Scholar]
38. Grady WM, Rajput A, Lutterbaugh JD, et al. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61(3): 900-2. [PubMed] [Google Scholar]
39. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004; 68(6): 1187-97. [PubMed] [Google Scholar]
40. Fiegl H, Millinger S, Mueller-Holzner E, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005; 65(4): 1141-5. [PubMed] [Google Scholar]
41. Kloten V, Becker B, Winner K, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 2013; 15(1): R4. [PubMed] [Google Scholar]
42. Mirza S, Sharma G, Parshad R, et al. Clinical Significance of Promoter Hypermethylation of ERb and RARb2 in Tumor and Serum DNA in Indian Breast Cancer Patients. Ann Surg Oncol 2012; 19(9): 3107-15. [PubMed] [Google Scholar]
43. Naeimi S. Study of P14/ARF Gene Promoter Methylation and Effect of Interleukin-17 Gene Polymorphism on this Methylation among Breast Cancer Patients. Iran South Med J 2016; 19(5): 809-18. (Persian) [Google Scholar]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
